284 related articles for article (PubMed ID: 22361010)
1. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Rudenko IN; Chia R; Cookson MR
BMC Med; 2012 Feb; 10():20. PubMed ID: 22361010
[TBL] [Abstract][Full Text] [Related]
2. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
3. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
Gilligan PJ
Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
8. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
Reichling LJ; Riddle SM
Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
[TBL] [Abstract][Full Text] [Related]
10. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S; Liu M
Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
Rudenko IN; Cookson MR
Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
[TBL] [Abstract][Full Text] [Related]
12. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
14. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
15. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Liu Z; Hamamichi S; Lee BD; Yang D; Ray A; Caldwell GA; Caldwell KA; Dawson TM; Smith WW; Dawson VL
Hum Mol Genet; 2011 Oct; 20(20):3933-42. PubMed ID: 21768216
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
19. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
